NCT07462507 2026-03-10
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Not yet recruiting
Clinical Trials
20 trialsNCT07458113 2026-03-09
BERLIN
Yale University
Phase 2 Not yet recruiting
NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT07449481 2026-03-04
A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07439172 2026-02-27
PRC
The Cooper Health System
Phase 2 Not yet recruiting
NCT07428616 2026-02-24
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Not yet recruiting
NCT07383649 2026-02-03
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06907485 2026-01-21
A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients
University of Pittsburgh
Phase 2 Not yet recruiting
NCT07343479 2026-01-15
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07206849 2025-10-29
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Nationwide Children's Hospital
Phase 2 Not yet recruiting
NCT07197008 2025-09-29
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06974370 2025-05-15
ACTION-Brain
University of Vermont Medical Center
Phase 2 Not yet recruiting
NCT06678867 2025-03-27
P5A
University College, London
Phase 2 Not yet recruiting
NCT06483672 2024-07-03
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06462079 2024-06-17
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
Guangzhou Medical University
Phase 2 Not yet recruiting
NCT06374888 2024-04-19
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT06210438 2024-01-18
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
Fudan University
Phase 2 Not yet recruiting
NCT06088056 2023-10-18
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
Fudan University
Phase 2 Not yet recruiting